Delivery Order SPE2DR25D3016-SPE2DR26FG2BK
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of VYVGART 400 mg/20 ml vials totaling $12,792.51 with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's substantial...
- The Defense Logistics Agency awarded a $34,113.36 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of VYVGART 400 mg/20 mL vials. This is a firm fixed-price, competitively awarded delivery order with an ultimate completion date of August 25, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $12,792.51 to AmerisourceBergen Drug Corp for VYVGART 400 mg/20 ml vials on August 26, 2025, with an ultimate completion date of September 17, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery...
- The Defense Logistics Agency awarded a $44,937.80 delivery order to AmerisourceBergen Drug Corp on December 5, 2025, for the supply of VYVGART 400 mg/20 ml vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of December 29, 2025, and performance to be executed at the contractor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $53,925.36 on December 2, 2025, for the supply of VYVGART 400 MG/20 ML vials. This competitive, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of December 23, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $34,113.36 firm fixed price delivery order to AmerisourceBergen Drug Corp for VYVGART 400 MG/20 ML vials on September 8, 2025, with completion targeted for September 29, 2025. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $8,987.56 on December 3, 2025, for the supply of Vyvgart 400 mg/20 ml vials. This competitively awarded, firm fixed-price contract is scheduled for completion by December 24, 2025, with performance to take place at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified suppliers. This delivery...
- The Defense Logistics Agency awarded a $12.8K delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Vyvgart 400 mg/20 ml vials. The contract is non-set-aside and competitively awarded with firm fixed pricing, with an ultimate completion date of September 3, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The U.S. Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Vyvgart 400 mg/20 ml vials. This competitive, firm fixed-price delivery order carries a ceiling value of $8,528.34 and is due for completion by August 29, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This award carries no set-aside designation,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a $25,585.02 delivery order by the Defense Logistics Agency on November 7, 2025, for VYVGART 400 mg/20 ml vials. The contract represents a firm fixed price delivery order with an ultimate completion date of December 2, 2025, and was competitively awarded without set-aside designation. This award is a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DR25D3016Indefinite Delivery Contract
- SPE2DR25D3016-SPE2DR26FG2BKDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $26,962.68 to AmerisourceBergen Drug Corp for the supply of VYVGART 400 MG/20 ML vials on a firm fixed price basis. The award, issued on December 10, 2025, with an ultimate completion date of January 2, 2026, represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's $999,999,999.00 Pharmaceutical Prime Vendor Global IDC (SPE2DX) running through December 2026, which serves as the primary vehicle for supplying pharmaceutical products and medical supplies to Department of Defense and other federal healthcare systems worldwide. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, has demonstrated sustained capability in meeting federal procurement requirements through competitive awards and maintains a comprehensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.0k | 12/9/25 |